Ergoteles LLC Exelixis, Inc. Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $1.08 Million - $1.21 Million	59,231 New	59,231 $1.13 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $2.69 Million - $3.13 Million	180,059 Added 844.75%	201,374 $3.23 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $171,601 - $243,722	10,944 Added 105.53%	21,315 $334,000
Q2 2022 Aug 12, 2022	SELL	$17.44 - $23.16 $374,384 - $497,175	-21,467 Reduced 67.43%	10,371 $216,000
Q1 2022 May 13, 2022	SELL	$17.03 - $22.67 $563,693 - $750,377	-33,100 Reduced 50.97%	31,838 $722,000
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $1.03 Million - $1.42 Million	64,938 New	64,938 $1.19 Million

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.